

Financial news for ITCI dated on 2020-05-07: Intra-Cellular Therapies Q1 EPS \$(0.730) Beats \$(0.930) Estimate, Sales \$1.083M Miss \$1.440M Estimate

Financial news for ITCI dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for ITCI dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ITCI dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for ITCI dated on 2020-04-02: Intra-Cellular Reports Initiation Of Promotional Activities For CAPLYTA For Treatment Of Schizophrenia In Adults

Financial news for ITCI dated on 2020-04-02: Intra-Cellular Therapies Initiates Promotional Activities For CAPLYTA For The Treatment Of Schizophrenia In Adults

Financial news for ITCI dated on 2020-03-23: Intra-Cellular Therapies Announces Availability of CAPLYTA for Adult Patients with Schizophrenia

Financial news for ITCI dated on 2020-03-17: 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades

Financial news for ITCI dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for ITCI dated on 2020-03-03: BTIG Research Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to \$68

Financial news for ITCI dated on 2020-03-02: Intra-Cellular Therapies Q4 EPS \$(0.74) Beats \$(0.81) Estimate, Sales \$60.613K

Financial news for ITCI dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for ITCI dated on 2020-02-20: Intra-Cellular Therapies Highlights Data From Pivotal Study Of CAPLYTA For Treatment Of Schizophrenia In Adults Published In JAMA Psychiatry

Financial news for ITCI dated on 2020-02-20: Evercore ISI Group Initiates Coverage On Intra-Cellular Therapies with Outperform Rating

Financial news for ITCI dated on 2020-02-18: 10 Biggest Price Target Changes For Tuesday

Financial news for ITCI dated on 2020-02-18: Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Raises Price Target to \$47

Financial news for ITCI dated on 2020-01-31: Intra-Cellular Therapies shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral.

Financial news for ITCI dated on 2020-01-31: JP Morgan Downgrades Intra-Cellular Therapies to Neutral, Raises Price Target to \$26

Financial news for ITCI dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for ITCI dated on 2020-01-09: 54 Biggest Movers From Yesterday

Financial news for ITCI dated on 2020-01-08: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ITCI dated on 2020-01-08: Intra-Cellular Therapies shares are trading lower after the company priced its 10 million share public offering of common stock at \$29.50 per share.

Financial news for ITCI dated on 2020-01-08: 50 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ITCI dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for ITCI dated on 2020-01-07: Intra-Cellular Therapies Prices 10M Share Public Offering of Common Stock @\$29.50/Share

Financial news for ITCI dated on 2020-01-07: The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

Financial news for ITCI dated on 2020-01-07: 15 Stocks Moving in Tuesday's Pre-Market Session

Financial news for ITCI dated on 2020-01-07: A Peek Into The Markets: US Stock Futures Up Ahead Of Economic Data

Financial news for ITCI dated on 2020-01-07: 5 Stocks To Watch For January 7, 2020

Financial news for ITCI dated on 2020-01-06: Intra-Cellular Therapies shares are trading lower after the company announced a proposed public offering of 10,000,000 shares of common stock.

Financial news for ITCI dated on 2020-01-06: Intra-Cellular Reports Commencement Of 10M Share Common Stock Offering

Financial news for ITCI dated on 2020-01-06: Intra-Cellular Therapies Files For Mixed Shelf Offering; Size Not Disclosed

Financial news for ITCI dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for ITCI dated on 2019-12-27: Intra-Cellular Therapies shares are trading lower. Not seeing any news to justify the price action. NOTE: Several stocks are trading on below-average volume due to the holidays.

Financial news for ITCI dated on 2019-12-24: Canaccord Genuity Reiterates Buy on Intra-Cellular Therapies, Raises Price Target to \$65

Financial news for ITCI dated on 2019-12-24: Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI

Financial news for ITCI dated on 2019-12-24: 20 Stocks Moving in Tuesday's Pre-Market Session

Financial news for ITCI dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for ITCI dated on 2019-12-24: Intra-Cellular Therapies shares are trading higher on continued momentum after the company announced it has received FDA approval for CAPLYTA for the treatment of schizophrenia in adults.

Financial news for ITCI dated on 2019-12-24: 78 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-12-23: Mid-Afternoon Market Update: Dow Rises 110 Points; Intra-Cellular Therapies Shares Spike Higher

Financial news for ITCI dated on 2019-12-23: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for ITCI dated on 2019-12-23: Mid-Day Market Update: Cincinnati Bell Jumps Following Acquisition News; Safe-T Group Shares Plunge

Financial news for ITCI dated on 2019-12-23: Intra-Cellular Therapies Soars To Multiyear High Following FDA Nod For Schizophrenia Drug

Financial news for ITCI dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for ITCI dated on 2019-12-23: Mid-Morning Market Update: Markets Open Higher; Culligan To Acquire AquaVenture For \$27.10/Share

Financial news for ITCI dated on 2019-12-23: Intra-Cellular Therapies Option Alert: Jan 17 \$15 Calls Sweep (2) near the Ask: 1500 @ \$11.35 vs 24600 OI; Ref=\$25.69

Financial news for ITCI dated on 2019-12-23: 16 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ITCI dated on 2019-12-23: Intra-Cellular Therapies shares are trading higher after the company announced it has received FDA approval for CAPLYTA for the treatment of schizophrenia in adults.

Financial news for ITCI dated on 2019-12-23: Intra-Cellular Therapies' CAPLYTA

Approved by the FDA for the Treatment of Schizophrenia in Adults

Financial news for ITCI dated on 2019-12-22: The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions

Financial news for ITCI dated on 2019-12-12: Intra-Cellular Therapies Option Alert: Dec 20 \$15 Calls at the Ask: 1495 @ \$0.801 vs 3582 OI; Ref=\$12.7

Financial news for ITCI dated on 2019-12-12: Intra-Cellular Therapies Highlights Lumateperone Presentations At Meeting Of American College Of Neuropsychopharmacology

Financial news for ITCI dated on 2019-12-10: 41 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for ITCI dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-11-29: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for ITCI dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ITCI dated on 2019-11-05: Intra-Cellular Therapies Q3 EPS \$(0.63) Up From \$(0.76) YoY

Financial news for ITCI dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for ITCI dated on 2019-10-03: 46 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-10-02: Intra-Cellular Therapies shares are trading higher on a potential rebound after the stock dropped more than 10% yesterday.

Financial news for ITCI dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for ITCI dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ITCI dated on 2019-10-01: Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.

Financial news for ITCI dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for ITCI dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for ITCI dated on 2019-09-13: Intra-Cellular Therapies shares are trading lower after the company filed for a common stock offering up to \$75 million.

Financial news for ITCI dated on 2019-09-12: Intra-Cellular Therapies Files For Up To \$75M Common Stock Offering

Financial news for ITCI dated on 2019-09-11: Intra-Cellular Therapies Director Alafi Buys 485,000 @ Avg Price: \$10.26

Financial news for ITCI dated on 2019-09-10: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ITCI dated on 2019-09-10: FDA: No Adcom Meeting For Intra-Cellular's Schizophrenia Drug

Financial news for ITCI dated on 2019-09-10: Mid-Morning Market Update: Markets Open Lower; HD Supply Posts Mixed Q2 Results

Financial news for ITCI dated on 2019-09-10: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for ITCI dated on 2019-09-10: Intra-Cellular Therapies shares are trading lower after the company announced that the FDA has informed the company it does not plan on scheduling an advisory committee meeting in connection with its review of the company's NDA for Lumateperone.

Financial news for ITCI dated on 2019-09-10: FDA Has Informed Intra-Cellular Therapies It Does Not Have Plans To Schedule An Advisory Committee Meeting In

Connection With Review Of Co.'s New Drug Application For Lumateperone

Financial news for ITCI dated on 2019-08-23: 33 Stocks Moving in Friday's Pre-Market Session

Financial news for ITCI dated on 2019-08-12: Benzinga's Top Upgrades, Downgrades For August 12, 2019

Financial news for ITCI dated on 2019-08-12: Jefferies Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces \$16 Price Target

Financial news for ITCI dated on 2019-08-08: JMP Securities Reiterates Market Outperform on Intra-Cellular Therapies, Lowers Price Target to \$21

Financial news for ITCI dated on 2019-08-07: Intra-Cellular Therapies Q2 EPS \$(0.68) Beats \$(0.83) Estimate

Financial news for ITCI dated on 2019-08-06: 70 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-08-05: 45 Stocks Moving In Monday's Mid-Day Session

Financial news for ITCI dated on 2019-08-05: Intra-Cellular Therapies shares are trading higher after the company announced it has reached an agreement to submit additional non-clinical information in connection with the FDA's ongoing review of the Company's New Drug application for lumateperone.

Financial news for ITCI dated on 2019-08-05: Intra-Cellular Therapies Reached an Agreement with the FDA for the Submission of Additional Non-Clinical Information for NDA Review of Lumateperone, PDUFA Date Extended 3 Months to December 27, 2019

Financial news for ITCI dated on 2019-07-24: A Look At Benzinga Pro's Most-Searches Tickers For July 24, 2019

Financial news for ITCI dated on 2019-07-24: Benzinga Pro's Top 10 Most-Searches Tickers For Morning of Wednesday., July 24, 2019

Financial news for ITCI dated on 2019-07-24: Intra-Cellular Therapies Option Alert: Aug 16 \$10 Puts at the Bid: 500 @ \$2.05 vs 14995 OI; Earnings 8/1 Before Open [est] Ref=\$8.22

Financial news for ITCI dated on 2019-07-24: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ITCI dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for ITCI dated on 2019-07-24: 60 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-07-23: Intra-Cellular Therapies Says FDA Cancelled Meeting to Allow Sufficient Time to Review This New, Any Forthcoming Information as They Continue NDA Review

Financial news for ITCI dated on 2019-07-23: STAT News Article Discusses FDA's Cancelling Of Advisory Committee Meeting To Review Intra-Cellular's Schizophrenia NDA

Financial news for ITCI dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for ITCI dated on 2019-07-23: Intra-Cellular Therapies Resume Trade

Financial news for ITCI dated on 2019-07-23: Intra-Cellular Therapies Option Alert: Aug 16 \$7.5 Puts Sweep (17) above Ask!: 985 @ \$0.439 vs 7285 OI; Earnings 8/1 Before Open [est] Ref=\$9.1

Financial news for ITCI dated on 2019-07-23: Intra-Cellular Therapies shares are trading lower after the FDA reported an advisory committee meeting with the company has been cancelled, citing 'new information' regarding the its NDA for its schizophrenia treatment.

Financial news for ITCI dated on 2019-07-23: Intra-Cellular Therapies Shares Resume Trade

Financial news for ITCI dated on 2019-07-23: FDA Reports Psychopharmacologic Drugs Advisory Committee Meeting With Intra-Cellular Therapies Has Been Cancelled Because Of New Information Regarding Application

Financial news for ITCI dated on 2019-07-23: Intra-Cellular Therapies Option Alert:

Aug 16 \$15 Calls Sweep (18) near the Ask: 500 @ \$0.85 vs 8990 OI; Earnings 8/1 Before Open [est] Ref=\$11.29

Financial news for ITCI dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for ITCI dated on 2019-07-09: A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019

Financial news for ITCI dated on 2019-07-09: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, July 9, 2019

Financial news for ITCI dated on 2019-07-09: 52 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-07-08: Mid-Afternoon Market Update: Dow Down 150 Points; Intra-Cellular Therapies Shares Plunge

Financial news for ITCI dated on 2019-07-08: A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019

Financial news for ITCI dated on 2019-07-08: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for ITCI dated on 2019-07-08: Mid-Day Market Update: Crude Oil Up Over 1%; Sol-Gel Technologies Shares Spike Higher

Financial news for ITCI dated on 2019-07-08: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, July 8, 2019

Financial news for ITCI dated on 2019-07-08: Mid-Morning Market Update: Markets Open Lower; Deutsche Bank To Cut 18K Jobs

Financial news for ITCI dated on 2019-07-08: What Caused The Opening Gap In Intra-Cellular Therapies?

Financial news for ITCI dated on 2019-07-08: Intra-Cellular Therapies Falls Following Results For Treatment Of Bipolar Depression

Financial news for ITCI dated on 2019-07-08: Intra-Cellular Therapies shares are trading lower after the company said its 401 Study of Lumateperone did not meet its primary endpoint.

Financial news for ITCI dated on 2019-07-08: Intra-Cellular Therapies Shares Resume Trading Higher After Announcing Mixed Study Results

Financial news for ITCI dated on 2019-07-08: Intra-Cellular Therapies Says Study 401 of Lumateperone Did not Meet its Primary Endpoint

Financial news for ITCI dated on 2019-07-08: Intra-Cellular Therapies' Phase 3 404 Trial of Lumateperone Met its Primary and Key Secondary Endpoints

Financial news for ITCI dated on 2019-07-08: Intra-Cellular Therapies Halted, News Pending

Financial news for ITCI dated on 2019-07-06: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

Financial news for ITCI dated on 2019-07-01: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for ITCI dated on 2019-06-18: 60 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-06-17: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for ITCI dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for ITCI dated on 2019-06-13: Intra-Cellular Therapies shares are trading higher after the FDA announced a Psychopharmacologic Drugs Advisory Committee meeting on July 31, 2019 to discuss the NDA for lumateperone.

Financial news for ITCI dated on 2019-06-13: UPDATE: Intra-Cellular Says Sees PDUFA Date For Lumateperone Sep. 27, 2019

Financial news for ITCI dated on 2019-06-13: Intra-Cellular Therapies Reports FDA

Advisory Committee Meeting To Review New Drug Application For Lumateperone For Treatment Of Schizophrenia In Adults

Financial news for ITCI dated on 2019-06-13: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for ITCI dated on 2019-06-13: 50 Biggest Movers From Yesterday

Financial news for ITCI dated on 2019-05-16: Intra-Cellular Therapies Option Alert: Fri \$10 Puts at the Bid: 8000 @ \$0.051 vs 21564 OI; Ref=\$12.67

Financial news for ITCI dated on 2019-05-08: Intra-Cellular Therapies Inc. Q1 EPS \$(0.63) Beats \$(0.87) Estimate

Financial news for ITCI dated on 2019-04-15: Intra-Cellular Therapies Presents Additional Results From its Open Label Safety Study of Lumateperone

Financial news for ITCI dated on 2019-03-21: Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols

Financial news for ITCI dated on 2019-02-27: Intra-Cellular Therapies Inc. Q4 EPS \$(0.75) Beats \$(0.91) Estimate

Financial news for ITCI dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for ITCI dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for ITCI dated on 2018-12-18: Intra-Cellular Therapies shares are trading lower after the company said it will not proceed with its Study 201 due to the expectation it would not meet its primary endpoint.

Financial news for ITCI dated on 2018-12-18: Intra-Cellular Therapies To Discontinue Study 201 In Alzheimer's Treatment After A Data Monitoring Committee Determined The Study Was Unlikely To Meet Its Primary Endpoint

Financial news for ITCI dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for ITCI dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for ITCI dated on 2018-12-12: Intra-Cellular Therapies Shares Tick Higher On Heavy Volume As Traders Circulate Price Target Raise To New Street High By RBC, Now At \$37

Financial news for ITCI dated on 2018-12-11: Intra-Cellular Therapies Highlights Will Present Long-Term Data From Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia At American College of Neuropsychopharmacology

Financial news for ITCI dated on 2018-12-11: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ITCI dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for ITCI dated on 2018-12-11: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ITCI dated on 2018-12-11: Intra-Cellular Therapies Announces FDA Acceptance Of New Drug Application For Lumateperone For The Treatment Of Schizophrenia

Financial news for ITCI dated on 2018-12-10: 48 Biggest Movers From Friday

Financial news for ITCI dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for ITCI dated on 2018-12-04: Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018

Financial news for ITCI dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for ITCI dated on 2018-11-15: Leerink Swann Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces \$27 Price Target

Financial news for ITCI dated on 2018-11-15: 76 Biggest Movers From Yesterday

Financial news for ITCI dated on 2018-11-14: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ITCI dated on 2018-11-13: Leerink Swann Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces \$27 Price Target

Financial news for ITCI dated on 2018-11-07: Intra-Cellular Therapies Inc. - Common Stock Q3 EPS \$(0.76) Beats \$(0.84) Estimate

Financial news for ITCI dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for ITCI dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for ITCI dated on 2018-10-23: Intra-Cellular Therapies Reports Favorable Safety Profile For ITI-214 In A Phase 1/2 Clinical Trial In Patients With Parkinson's Disease

Financial news for ITCI dated on 2018-10-22: Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report

Financial news for ITCI dated on 2018-10-22: REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma

Financial news for ITCI dated on 2018-10-17: Intra-Cellular Therapies To Present Top-Line Results From ITI-214 Phase 1/2 Clinical Trial In Patients With Parkinson's Disease At 2018 American Neurological Association Annual Meeting. Oct. 21-24

Financial news for ITCI dated on 2018-09-28: Intra-Cellular Therapies Reports Completion Of Submission Of New Drug Application For Lumateperone For Treatment Of Schizophrenia

Financial news for ITCI dated on 2018-08-23: Cantor Fitzgerald Initiates Coverage On Intra-Cellular Therapies with Overweight Rating, Announces \$32 Price Target

Financial news for ITCI dated on 2018-08-02: Intra-Cellular Therapies Inc. Q2 EPS \$(0.68) Beats \$(0.76) Estimate

Financial news for ITCI dated on 2018-07-23: Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Results in Preclinical Models of Heart Failure

Financial news for ITCI dated on 2018-07-21: Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

Financial news for ITCI dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for ITCI dated on 2018-06-06: Intra-Cellular Therapies Reports Initiation Of Rolling Submission Of NDA For Lumateperone For Treatment Of Schizophrenia

Financial news for ITCI dated on 2018-05-03: Intra-Cellular Therapies Inc. - Common Stock Q1 EPS \$(0.65) Beats \$(0.66) Estimate

Financial news for ITCI dated on 2018-04-27: Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences

Financial news for ITCI dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for ITCI dated on 2018-04-02: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for ITCI dated on 2018-04-02: Intra-Cellular Therapies Shares Down 15.7% In Sympathy With Alkermes After FDA Refuses To Review ALKS-5461; Earlier, Stat News' Adam F Tweeted: 'Anyone confident in \$ITCI now? I wouldn't be.'

Financial news for ITCI dated on 2018-04-02: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for ITCI dated on 2018-03-13: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ITCI dated on 2018-03-13: Intra-Cellular Therapies Announces

'Positive' Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia

Financial news for ITCI dated on 2018-03-05: 42 Biggest Movers From Friday

Financial news for ITCI dated on 2018-03-01: Intra-Cellular Therapies Reports Q4 EPS \$(0.56) vs \$(0.54) Est.

Financial news for ITCI dated on 2018-02-26: JP Morgan Initiates Coverage On Intra-Cellular Therapies with Overweight Rating, Announces \$25.00 Price Target

Financial news for ITCI dated on 2018-02-08: RBC Capital Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces \$33.00 Price Target

Financial news for ITCI dated on 2017-12-15: Benzinga's Top Upgrades, Downgrades For December 15, 2017

Financial news for ITCI dated on 2017-12-15: Canaccord Genuity Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces \$31.00 Price Target

Financial news for ITCI dated on 2017-12-07: Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology

Financial news for ITCI dated on 2017-11-21: 35 Biggest Movers From Yesterday

Financial news for ITCI dated on 2017-11-20: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for ITCI dated on 2017-11-20: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for ITCI dated on 2017-11-20: Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

Financial news for ITCI dated on 2017-11-08: SunTrust Robinson Humphrey Upgrades Intra-Cellular Therapies to Buy

Financial news for ITCI dated on 2017-11-08: Intra-Cellular Therapies Reports Q3 EPS \$(0.53) vs \$(0.62) Est., Sales \$30.754K vs \$60K Est.

Financial news for ITCI dated on 2017-10-03: Intra-Cellular Therapies Reports Commencement Of Enrollment Of Trial Evaluating ITI-214 In Patients With Parkinson's Disease

Financial news for ITCI dated on 2017-09-28: Intra-Cellular Therapies Prices ~9.67M Share Offering @\$15.50/Share

Financial news for ITCI dated on 2017-09-26: Intra-Cellular Reports Commencement Of \$150M Share Common Stock Offering

Financial news for ITCI dated on 2017-09-07: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ITCI dated on 2017-09-07: Intra-Cellular Therapies Reports Topline Data Form First Part Of Open-Label Safety Switching Study Showed No Dose Titration Of Lumateperone Required For 6-Week Treatment Duration

Financial news for ITCI dated on 2017-08-30: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for ITCI dated on 2017-08-30: Ladenburg Thalmann Upgrades Intra-Cellular Therapies to Buy

Financial news for ITCI dated on 2017-08-30: Benzinga's Top Upgrades, Downgrades For August 30, 2017

Financial news for ITCI dated on 2017-08-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ITCI dated on 2017-08-24: Benzinga's Top Upgrades, Downgrades For August 24, 2017

Financial news for ITCI dated on 2017-08-24: JMP Securities Upgrades Intra-Cellular Therapies to Market Outperform

Financial news for ITCI dated on 2017-08-23: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Express Shares Rise After Strong Q2 Results

Financial news for ITCI dated on 2017-08-23: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for ITCI dated on 2017-08-23: Mid-Day Market Update: La-Z-Boy Drops After Q1 Miss; Paratek Pharmaceuticals Shares Rise

Financial news for ITCI dated on 2017-08-23: BB Biotech Reports 5.1% Stake In INtra-Cellular Therapies

Financial news for ITCI dated on 2017-08-23: Mid-Morning Market Update: Markets Open Lower; Lowe's Earnings Miss Expectations

Financial news for ITCI dated on 2017-08-23: Intra-Cellular Therapies Reports FDA Informed Co. That Data on lumateperone To Support Position That Metabolic Pathway In Animals Are Different Than Humans, Which Indicates That Toxicity Observed In Animals Isn't Relevant To Humans

Financial news for ITCI dated on 2017-08-09: Intra-Cellular Therapies Reports Q2 EPS \$(0.41) vs \$(0.74) Est., Sales \$114.741K vs \$30K Est.

Financial news for ITCI dated on 2017-07-12: Benzinga's Option Alert Recap From July 12

Financial news for ITCI dated on 2017-07-12: Intracellular Therapies Option Alert: Aug 18 \$10 Calls at the Ask: 900 @ \$2.351 vs 387 OI; Ref=\$11.85

Financial news for ITCI dated on 2017-05-12: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for ITCI dated on 2017-05-10: Intra Cellular Therapies Pops to High of \$10.15 on Volume

Financial news for ITCI dated on 2017-05-10: Intra-Cellular Therapies Reports Q1 EPS \$(0.62) vs \$(0.72) Est.

Financial news for ITCI dated on 2017-05-08: Intra-Cellular Therapies Presents Data 'Supporting' the Potential for Potent and Rapid Antidepressant Activity with Lumateperone

Financial news for ITCI dated on 2017-05-02: 18 Biggest Mid-Day Losers For Tuesday

Financial news for ITCI dated on 2017-05-02: 5 Biggest Price Target Changes For Tuesday

Financial news for ITCI dated on 2017-05-02: Benzinga's Top Upgrades, Downgrades For May 2, 2017

Financial news for ITCI dated on 2017-05-02: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ITCI dated on 2017-05-02: Leerink Swann Downgrades Intra-Cellular Therapies to Market Perform

Financial news for ITCI dated on 2017-05-02: Ladenburg Thalmann Downgrades Intra-Cellular Therapies to Neutral

Financial news for ITCI dated on 2017-05-01: 15 Biggest Mid-Day Losers For Monday

Financial news for ITCI dated on 2017-05-01: PiperJaffray Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to \$10.00

Financial news for ITCI dated on 2017-05-01: Mid-Morning Market Update: Markets Mostly Higher; DISH Network Profit Tops Estimates

Financial news for ITCI dated on 2017-05-01: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for ITCI dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for ITCI dated on 2017-03-02: 25 Biggest Mid-Day Gainers For Thursday

Financial news for ITCI dated on 2017-03-01: IntraCellular Pops to High of \$13.41 on Volume

Financial news for ITCI dated on 2017-03-01: Intra-Cellular Reports Q4 EPS \$(0.64) vs \$(0.77) Est., Sales \$97.895K vs \$20K Est.

Financial news for ITCI dated on 2016-12-22: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for ITCI dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On

Intra-Cellular Therapies at Overweight

Financial news for ITCI dated on 2016-12-08: Intra-Cellular Therapies Shares Down 3.33% On Above Average Volume, Despite Filing After-Hours Wednesday Showing Alafi Capital Purchase Of 65K Shares

Financial news for ITCI dated on 2016-12-07: Intra-Cellular Therapies, Inc.: Alafi Christopher D (Director, 10%+) Buys 65,000 @ Avg Price: \$16.27 (Form4)

Financial news for ITCI dated on 2016-12-06: 8 Stocks That Rallied Three Days On Increasing Volume

Financial news for ITCI dated on 2016-11-09: Intra-Cellular Q3 EPS \$(0.70) vs \$(0.84) Est, Revenue \$4.36K

Financial news for ITCI dated on 2016-10-03: Chipotle, Viacom And More: Fast Money Picks For October 3

Financial news for ITCI dated on 2016-09-29: Technical Alert: Intra-Cellular Therapies Fails To Rebound After Crashing

Financial news for ITCI dated on 2016-09-29: Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Financial news for ITCI dated on 2016-09-29: 12 Biggest Mid-Day Losers For Thursday

Financial news for ITCI dated on 2016-09-29: Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Financial news for ITCI dated on 2016-09-29: Stocks Hitting 52-Week Lows

Financial news for ITCI dated on 2016-09-29: Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Financial news for ITCI dated on 2016-09-29: 7 Biggest Price Target Changes For Thursday

Financial news for ITCI dated on 2016-09-29: Benzinga's Top Downgrades

Financial news for ITCI dated on 2016-09-29: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for ITCI dated on 2016-09-29: SunTrust Robinson Humphrey Downgrades Intra-Cellular Therapies to Neutral

Financial news for ITCI dated on 2016-09-29: JMP Securities Downgrades Intra-Cellular Therapies to Market Perform

Financial news for ITCI dated on 2016-09-28: 4 After-Hours Movers: Earnings, FDA Trials & Guide-Downs

Financial news for ITCI dated on 2016-09-28: Intra-Cellular Shares to Resume Trade at 4:30 p.m. EDT

Financial news for ITCI dated on 2016-09-28: UPDATE: Intra-Cellular Says Active Control, Risperidone, Did Separate from Placebo; ITI-007 Statistically Significantly Better Than Risperidone on Key Safety, Tolerability Parameters

Financial news for ITCI dated on 2016-09-28: Intra-Cellular Therapeutics Reports Top-Line Results from Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia: Neither Dose Separated from Placebo on Primary Endpoint

Financial news for ITCI dated on 2016-09-28: ITI Shares Halted News Pending

Financial news for ITCI dated on 2016-09-19: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for ITCI dated on 2016-09-16: Option Alert: ITCI Nov16 35.0 Puts: 900 @ ASK \$6.40: 1010 traded vs 73 OI: Earnings 11/3 \$44.42 Ref

Financial news for ITCI dated on 2016-08-04: Intra-Cellular Therapies Reports Q2 EPS \$(0.71) vs. Est. \$(0.79), Rev. \$228K vs. Est. \$20K

Financial news for ITCI dated on 2016-06-30: Intra-Cellular Reports Completion of Enrollment for ITI-007-302 Phase 3 Trial for Treatment of Schizophrenia

Financial news for ITCI dated on 2016-06-28: Intra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical Trial

Financial news for ITCI dated on 2016-06-10: Option Alert: SWEEP (SELL) - ITCI Aug \$45 Call - 1000 @ 3.25 in 4 orders. 1000 traded. OI: 738

Financial news for ITCI dated on 2016-06-02: Piper Jaffray Initiates Coverage on Intra-Cellular Therapies at Overweight, Announces \$57.00 PT

Financial news for ITCI dated on 2016-06-01: Piper Jaffray Initiates Coverage on Intra-Cellular Therapies at Overweight, Announces \$57.00 PT

Financial news for ITCI dated on 2016-04-28: Intra-Cellular Reports Q1 EPS \$(0.64) vs \$(0.78) Est.

Financial news for ITCI dated on 2016-04-06: Intra-Cellular Therapies Presents Additional ITI-007 Data at SIRS Conference

Financial news for ITCI dated on 2016-03-07: The Most Notable Insider Buys And Sells Of Last Week

Financial news for ITCI dated on 2016-03-02: 3 Biotech Companies With Recent Large Insider Buying

Financial news for ITCI dated on 2016-02-25: Intra-Cellular Therapies Reports Q4 EPS \$(0.67) vs. Est. \$(0.90)

Financial news for ITCI dated on 2016-01-17: 10 Stocks Moving On Friday's After-Hours Session

Financial news for ITCI dated on 2016-01-08: 12 Biotechs With Binary Events Coming This Year

Financial news for ITCI dated on 2015-12-09: Intra-Cellular Therapies Presents Additional Efficacy and Safety Data From the Positive Phase 3 Clinical Trial of ITI-007, Met Primary Endpoint Demonstrating Statistically Over Placebo

Financial news for ITCI dated on 2015-09-28: Intra-Cellular Therapies Announces Closing of \$345 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares

Financial news for ITCI dated on 2015-09-23: Benzinga's Volume Movers

Financial news for ITCI dated on 2015-09-21: Intra-Cellular Therapies Reports Completion of Phase 1 Studies for ITI-214, a Phosphodiesterase Type 1 Inhibitor, and Assumes IND Sponsorship for ITI-214

Financial news for ITCI dated on 2015-09-21: Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock, \$300M

Financial news for ITCI dated on 2015-09-17: Benzinga's Volume Movers

Financial news for ITCI dated on 2015-09-17: Stocks Hitting 52-Week Highs

Financial news for ITCI dated on 2015-09-17: Benzinga's Top #PreMarket Gainers

Financial news for ITCI dated on 2015-09-16: Mid-Afternoon Market Update: Cracker Barrel Drops Following Q4 Results; Intra-Cellular Therapies Shares Jump

Financial news for ITCI dated on 2015-09-16: Mid-Day Market Update: Crude Oil Surges Over 5%; Paycom Software Shares Tumble

Financial news for ITCI dated on 2015-09-16: Mid-Morning Market Update: Markets Mixed; FedEx Earnings Miss Estimates

Financial news for ITCI dated on 2015-09-16: Benzinga's Volume Movers

Financial news for ITCI dated on 2015-09-16: Stocks Hitting 52-Week Highs

Financial news for ITCI dated on 2015-09-16: Morning Market Gainers

Financial news for ITCI dated on 2015-09-16: Benzinga's Top #PreMarket Gainers

Financial news for ITCI dated on 2015-09-16: Intra-Cellular Therapies +32% Following Announcement of Positive Top Line Results For ITI-007 First Phase 3 Trial

Financial news for ITCI dated on 2015-09-16: Intra-Cellular Therapies Announces Positive Top Line Results For ITI-007 First Phase 3 Trial

Financial news for ITCI dated on 2015-09-01: Intra-Cellular Therapies Reports Publication of Positive Phase 2 Schizophrenia Study in the Journal Biological Psychiatry

Financial news for ITCI dated on 2015-07-15: Little Bear Reports Intra-Cellular Therapies Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

Financial news for ITCI dated on 2015-06-23: Intra-Cellular Therapies Initiates Randomization for ITI-007-302 Phase 3 Trial in Schizophrenia

Financial news for ITCI dated on 2015-06-17: SunTrust's 5 Biotech Picks For The Next 6 Months

Financial news for ITCI dated on 2015-06-15: Intra-Cellular Therapies Reports Closing of Enrollment in ITI-007-301 Phase 3 Trial for Treatment of Schizophrenia Candidate

Financial news for ITCI dated on 2015-05-18: Intra-Cellular Reported Will Further Analyze Phase 2 Trial of ITI-007 in Schizophrenia at Annual Meeting of APA

Financial news for ITCI dated on 2015-05-06: Benzinga's Top Initiations

Financial news for ITCI dated on 2015-05-06: SunTrust Robinson Humphrey Initiates Intra-Cellular Therapies At Buy

Financial news for ITCI dated on 2015-05-06: SunTrust Robinson Humphrey Initiates Coverage on Intra-Cellular Therapies at Buy, Announces \$50.00 PT

Financial news for ITCI dated on 2015-04-14: RBC Capital Initiates Coverage on Intra-Cellular Therapies at Outperform, Announces \$41.00 PT

Financial news for ITCI dated on 2015-03-31: Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Studies

Financial news for ITCI dated on 2015-03-12: Intra-Cellular Therapies Shareholder Sosland Buys 250,000 Shares @\$24.00/Share -Form 4

Financial news for ITCI dated on 2015-03-12: Intra-Cellular Reports Q4 EPS \$(0.52) vs. Est. \$(0.37), Rev. \$65.8K vs. Est. \$120K

Financial news for ITCI dated on 2015-03-06: US Stock Futures Mixed, All Eyes On Jobs Data

Financial news for ITCI dated on 2015-03-06: Intra-Cellular Prices 4.75M Share Offering at \$24.00/Share

Financial news for ITCI dated on 2015-03-04: Intra-Cellular Therapies Announces 4.25M Share Offering

Financial news for ITCI dated on 2014-12-23: UPDATE: JMP Securities Initiates Coverage On Intra-Cellular Therapies

Financial news for ITCI dated on 2014-12-23: JMP Securities Initiates Coverage on Intra-Cellular Therapies at Market Outperform, Announces \$26.00 PT

Financial news for ITCI dated on 2014-11-25: Intra-Cellular Therapies Announces Enrollment Of First Patient In Phase 3 Trial Of ITI-007

Financial news for ITCI dated on 2014-11-21: Intra-Cellular Therapies Announces Additional Results From Phase I/II Clinical Trial for ITI-007

Financial news for ITCI dated on 2014-11-03: Intra-Cellular Therapies and Takeda Announce Mutual Termination of Collaboration to Develop Phosphodiesterase (PDE1) Inhibitors for CNS Disorders

Financial news for ITCI dated on 2014-10-13: US Stock Futures Signal Higher Start On Wall Street

Financial news for ITCI dated on 2014-10-13: Intra-Cellular Therapies Announces Positive Topline Safety Results From Phase I/II Clinical Trial for ITI-007

Financial news for ITCI dated on 2014-10-06: Intra-Cellular Therapies To Present Results From Phase I/II Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia At The American Neurological Association 139th Annual Meeting

Financial news for ITCI dated on 2014-08-29: S-3 Filing from Intra-Cellular Therapies Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for ITCI dated on 2014-08-12: Intra-Cellular Therapies Reports Q2 EPS of \$(0.15); Revenue of \$219.24K